revenue $0, net income -$21.3M. SCYNEXIS pivots to rare kidney disease, acquires SCY-770 for upfront

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Company acquired SCY-770 from Poxel for $8M upfront plus up to $188M in milestones, shifting strategic focus from antifungal infections to ADPKD, a rare kidney disease affecting 140,000-160,000 U.S. patients. Phase 2 trial planned for Q4 2026.

  MD&A: SCY-770 Acquisition verify on EDGAR →
• high

  Raised $40M gross proceeds in March 2026 private placement, issuing 34.75M shares plus warrants exercisable at $1.20 through 2031. Cash position increased to $72.4M from $53.8M year-over-year, funding the ADPKD program pivot.

  MD&A: Private Placement verify on EDGAR →
• high

  Securities class action and derivative suits over manufacturing contamination allegations no longer disclosed. Baseline showed active litigation with motion to dismiss filed; current filing provides no status update on resolution or financial impact.

  Legal Proceedings view on EDGAR →